Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Scott Egon Eggener

Title(s)Department Chair, Urology
SchoolMedicine
Emailseggener@ucla.edu
vCardDownload vCard
    Other Positions
    Title(s)HS Clinical Instructor, Urology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mesothelioma of the Tunica Vaginalis Testis. Clin Genitourin Cancer. 2025 Aug 07; 23(6):102409. Lazarovich A, Raster G, Tremblay S, Dahmen AS, Kwon JW, Paner GP, Mitchell O, Kindler HL, Eggener S. PMID: 40914026.
      View in: PubMed   Mentions:    Fields:    
    2. A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: Erratum. J Urol. 2025 Aug; 214(2):238. Lazarovich A, Vigneswaran H, Palsdottir T, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Plym A, Wiklund F, Grönberg H, Murphy AB, Eggener S. PMID: 40626447.
      View in: PubMed   Mentions:    Fields:    
    3. Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. 2025;88:8-10. Eur Urol. 2025 Sep; 88(3):e59-e60. Cooperberg MR, Grummet J, Eggener SE. PMID: 40514254.
      View in: PubMed   Mentions:    Fields:    
    4. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum. J Urol. 2025 Jul; 214(1):111. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. PMID: 40488244.
      View in: PubMed   Mentions:    Fields:    
    5. A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2025 May 30. Katipally RR, Rajeev-Kumar G, Solanki AA, Arif F, Eggener SE, Sidana A, Szmulewitz RZ, Stadler WM, Sweis RF, Pitroda SP, Liauw SL. PMID: 40451439.
      View in: PubMed   Mentions:    Fields:    
    6. MXene and prostate cancer: is there promising news? Nanomedicine (Lond). 2025 05; 20(9):1001-1014. Fattahi MR, Baghlani M, Eggener SE, Dehghani M, Khani MM, Kajbafzadeh A. PMID: 40235346; PMCID: PMC12051545.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 Sep; 214(3):272-279. Hu B, Alsyouf M, Farkouh A, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black PC, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Daneshmand S. PMID: 40203124.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025 May; 213(5):590-599. Lazarovich A, Vigneswaran H, Palsdottir T, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Plym A, Wiklund F, Grönberg H, Murphy AB, Eggener S. PMID: 40202133.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 04; 23(4). Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. PMID: 40203876.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 01; 117(4):685-691. Zhao Y, Gulati R, Yang Z, Newcomb L, Zheng Y, Zhu K, Liu M, Heijnsdijk EAM, Haffner MC, Cooperberg M, Eggener SE, De Marzo AM, Kibel AS, Rizopoulos D, Hall IJ, Etzioni R. PMID: 39565901; PMCID: PMC11972683.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review. Prostate Cancer Prostatic Dis. 2025 Mar 27. Ghai S, Ni TT, Pavlovich CP, Futterer JJ, Schade GR, Sanchez-Salas R, Cornud F, Eggener S, Feller JF, George AK, Villers A, de la Rosette J. PMID: 40140552.
      View in: PubMed   Mentions:    Fields:    
    12. When is prostate cancer really cancer? J Natl Cancer Inst. 2025 Mar 01; 117(3):402-405. Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE, CANCER-GG1 Writing Group . PMID: 39350309.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Nat Genet. 2025 Feb; 57(2):334-344. Hoffmann TJ, Graff RE, Madduri RK, Rodriguez AA, Cario CL, Feng K, Jiang Y, Wang A, Klein RJ, Pierce BL, Eggener S, Tong L, Blot W, Long J, Goss LB, Darst BF, Rebbeck T, Lachance J, Andrews C, Adebiyi AO, Adusei B, Aisuodionoe-Shadrach OI, Fernandez PW, Jalloh M, Janivara R, Chen WC, Mensah JE, Agalliu I, Berndt SI, Shelley JP, Schaffer K, Machiela MJ, Freedman ND, Huang WY, Li SA, Goodman PJ, Till C, Thompson I, Lilja H, Ranatunga DK, Presti J, Van Den Eeden SK, Chanock SJ, Mosley JD, Conti DV, Haiman CA, Justice AC, Kachuri L, Witte JS. PMID: 39930085; PMCID: PMC11821537.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Feb 20; 43(6):748-758. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. PMID: 39787437.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    15. Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025 Jan; 7(1):e240156. Chatterjee A, Yousuf AN, Engelmann R, Harmath C, Lee G, Medved M, Jamison EB, Lorente Campos A, Gundogdu B, Gerber G, Reynolds LF, Modi PK, Antic T, Giurcanu M, Eggener S, Karczmar GS, Oto A. PMID: 39836080; PMCID: PMC11791675.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    16. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2025 Jul-Aug; 15(4):e350-e361. Ballas LK, Reddy CA, Han HR, Makar JB, Mian O, Broughman J, de Bustamante C, Eggener S, Liauw SL, Abramowitz M, Montoya C, Tendulkar R. PMID: 39733964.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2025 Apr; 135(4):621-628. Antonelli L, Heidenreich A, Bagrodia A, Amini A, Baky F, Branger N, Cazzaniga W, Clinton TN, Daneshmand S, Djaladat H, Eggener S, Ghoreifi A, Hamilton RJ, Ho M, Sexton WJ, Nazzani S, Nicol D, Nicolai N, Olson K, Paffenholz P, Porter J, Qian Z, Rocco NR, Yerrapragada A, Stroup SP, Tachibana I, Terbuch A, Singla N, Cary C, Fankhauser CD, EAU-YAU Penile and Testis Cancer Working Group. PMID: 39662898.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR. Eur Urol. 2025 Feb; 87(2):238-239. Eggener S, Liauw SL. PMID: 39616001.
      View in: PubMed   Mentions:    Fields:    
    19. Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. Eur Urol Focus. 2024 Nov 16. Ghoreifi A, Sheybaee Moghaddam F, Mitra AP, Khanna A, Singh A, Chavarriaga J, Moon SC, Goolam AS, Chuang R, Rich JM, Baky FJ, Ho M, Roberts J, Gill IS, Porter JR, Ahmadi N, Mehrazin R, Sfakianos JP, Rais-Bahrami S, Bagrodia A, Hamilton RJ, Eggener S, Rawal S, Ward JF, Djaladat H. PMID: 39551650.
      View in: PubMed   Mentions: 2     Fields:    
    20. Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879. Huang D, Lynch C, Serra LM, Sweis RF, Chang PJ, Stadler WM, Szmulewitz RZ, O'Donnell PH, Sidana A, Eggener SE, Shalhav AL, Liauw SL, Pitroda SP. PMID: 39529961; PMCID: PMC11551534.
      View in: PubMed   Mentions:
    21. Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences. Cancers (Basel). 2024 Oct 16; 16(20). Chatterjee A, Fan X, Slear J, Asare G, Yousuf AN, Medved M, Antic T, Eggener S, Karczmar GS, Oto A. PMID: 39456593; PMCID: PMC11505680.
      View in: PubMed   Mentions: 3  
    22. Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2025 Feb; 135(2):339-345. Lazarovich A, Kristof TW, Steadman S, Dahmen AS, Josephson MA, Barth R, Morgan TM, Timsit MO, Eggener S. PMID: 39385314; PMCID: PMC11745990.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. medRxiv. 2024 Aug 20. Hoffmann TJ, Graff RE, Madduri RK, Rodriguez AA, Cario CL, Feng K, Jiang Y, Wang A, Klein RJ, Pierce BL, Eggener S, Tong L, Blot W, Long J, Goss LB, Darst BF, Rebbeck T, Lachance J, Andrews C, Adebiyi AO, Adusei B, Aisuodionoe-Shadrach OI, Fernandez PW, Jalloh M, Janivara R, Chen WC, Mensah JE, Agalliu I, Berndt SI, Shelley JP, Schaffer K, Machiela MJ, Freedman ND, Huang WY, Li SA, Goodman PJ, Till C, Thompson I, Lilja H, Ranatunga DK, Presti J, Van Den Eeden SK, Chanock SJ, Mosley JD, Conti DV, Haiman CA, Justice AC, Kachuri L, Witte JS. PMID: 37961155; PMCID: PMC10635224.
      View in: PubMed   Mentions:
    24. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10; 42(32):3806-3816. Vigneswaran HT, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Eggener S, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Palsdottir T, Plym A, Wiklund F, Grönberg H, Murphy AB, SEPTA STHLM3 Study Group. PMID: 39038251.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    25. Overcoming the Code Duello: Achieving Long-term Cure and Optimizing Quality of Life in Testicular Cancer. Eur Urol Focus. 2024 May; 10(3):355-356. Fankhauser CD, Eggener S. PMID: 39013684.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Survival outcomes and molecular drivers of testicular cancer in hispanic men. Urol Oncol. 2024 09; 42(9):293.e1-293.e7. Rezaee ME, Elias R, Li HL, Agrawal P, Pallauf M, Enikeev D, Ged Y, Eggener S, Singla N. PMID: 38821727.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. Transplantation. 2024 12 01; 108(12):2336-2350. Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP. PMID: 38771067.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103. Rajeev-Kumar G, Pitroda SP, Szmulewitz RZ, Skolarus T, Eggener SE, Liauw SL. PMID: 38781786.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774466; PMCID: PMC11108024.
      View in: PubMed   Mentions: 3  
    30. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774467; PMCID: PMC11107999.
      View in: PubMed   Mentions: 1  
    31. Ex-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy. Fertil Steril. 2024 Jun; 121(6):1069-1071. Villota CK, Hou SW, Judge C, Eggener S, Paner G, Raheem OA. PMID: 38403108.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. Eur Urol. 2024 Jul; 86(1):1-3. Vickers AJ, Assel M, Cooperberg MR, Fine SW, Eggener S. PMID: 38278665.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    33. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group. PMID: 38261983; PMCID: PMC11637124.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    34. Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3. Ho MD, Yeo KJ, Eggener SE. PMID: 37639675.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373. Berlin A, Ramotar M, Santiago AT, Liu Z, Li J, Wolinsky H, Wallis CJD, Chua MLK, Paner GP, van der Kwast T, Cooperberg MR, Vickers AJ, Urbach DR, Eggener SE. PMID: 37285311; PMCID: PMC10637044.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 12 01; 41(34):5296-5305. Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD, EAU-YAU Penile and Testis Cancer Working Group. PMID: 37656935.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638. Yim K, Ma C, Carlsson S, Lilja H, Mucci L, Penney K, Kibel AS, Eggener S, Preston MA. PMID: 37384841; PMCID: PMC10894656.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    38. Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228. Lee G, Chatterjee A, Harmath C, Karademir I, Engelmann R, Yousuf A, Islam S, Karczmar G, Oto A, Giurcanu M, Antic T, Eggener S. PMID: 37358605.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    39. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. 2023 11; 9(6):966-973. Saoud R, Woranisarakul V, Paner GP, Ramotar M, Berlin A, Cooperberg M, Eggener SE. PMID: 37117112.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023 07; 210(1):54-63. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. PMID: 37096575; PMCID: PMC11321723.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    41. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 07; 210(1):46-53. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. PMID: 37096582; PMCID: PMC11060750.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansPHPublic Health
    42. Renaming Grade Group 1 Prostate "Cancer" From a Pathology Perspective: A Call for Multidisciplinary Discussion. Adv Anat Pathol. 2023 Sep 01; 30(5):293-300. Paner GP, Zhou M, Simko JP, Eggener SE, van der Kwast T. PMID: 37072903.
      View in: PubMed   Mentions: 1     Fields:    
    43. Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023 07; 210(1):38-45. Ho MD, Ross AE, Eggener SE. PMID: 37042807.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Reply to X. Farré et al. JCO Glob Oncol. 2023 04; 9:e2300015. Vickers A, Berlin A, Paner G, Cooperberg M, Wolinsky H, Eggener S. PMID: 37099737; PMCID: PMC10281445.
      View in: PubMed   Mentions:    Fields:    
    45. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018. Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black P, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Luo C, Li M, Hu B. PMID: 36913642.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    46. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154. Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. PMID: 36787661.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Reply to M. Baboudjian et al. J Clin Oncol. 2023 Mar 01; 41(7):1493-1494. Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR. PMID: 36459669.
      View in: PubMed   Mentions:    Fields:    
    48. Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14. Ghoreifi A, Mitra AP, McClintock G, Baky F, McDowell Z, Lavallée E, Saoud R, Cai J, Gill IS, Sfakianos J, Porter J, Bagrodia A, Ahmadi N, Eggener S, Ward JF, Djaladat H. PMID: 36437156.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20. Witmer HDD, Dhiman A, Giurcanu M, Eng OS, Eggener S, Kindler HL, Turaga KK. PMID: 36319552.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm. Eur Urol. 2023 04; 83(4):304-306. Vickers AJ, Cooperberg MR, Eggener SE. PMID: 36280498.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    51. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 01; 209(1):49-57. Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE. PMID: 36129376.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160. Andolfi C, Vickers AJ, Cooperberg MR, Carroll PR, Cowan JE, Paner GP, Helfand BT, Liauw SL, Eggener SE. PMID: 35987380; PMCID: PMC10515713.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    53. Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups. BMC Urol. 2022 Jul 18; 22(1):107. Meza J, Babajide R, Saoud R, Sweis J, Abelleira J, Helenowski I, Jovanovic B, Eggener S, Miller FH, Horowitz JM, Casalino DD, Murphy AB. PMID: 35850677; PMCID: PMC9295380.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis. 2022 09; 25(3):444-452. Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K, Kenfield SA, Eggener SE, Price C, Davuluri M, Byrne N, Bivalacqua TJ, Loeb S. PMID: 35790788; PMCID: PMC12522196.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    55. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J Urol. 2022 07; 208(1):26-33. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. PMID: 35536141.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    56. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022 07; 208(1):10-18. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. PMID: 35536144.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    57. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 07; 208(1):19-25. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. PMID: 35536148.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    58. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 09 20; 40(27):3110-3114. Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR. PMID: 35436144.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    59. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. 2022 10; 82(4):341-351. Nyame YA, Cooperberg MR, Cumberbatch MG, Eggener SE, Etzioni R, Gomez SL, Haiman C, Huang F, Lee CT, Litwin MS, Lyratzopoulos G, Mohler JL, Murphy AB, Pettaway C, Powell IJ, Sasieni P, Schaeffer EM, Shariat SF, Gore JL. PMID: 35367082.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    60. Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative? Eur Urol. 2022 08; 82(2):161-162. Modi PK, Eggener SE. PMID: 35346513.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512. Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, Baky F, Cazzaniga W, Mayer E, Nicol D, Islamoglu E, de Vergie S, Saoud R, Eggener SE, Nazzani S, Nicolai N, Hugar L, Sexton WJ, Matei DV, De Cobelli O, Cheaib J, Pierorazio PM, Porter J, Hermanns T, Hamilton RJ, Hiester A, Albers P, Clarke N, Mattei A. PMID: 35279732.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    62. Reply by Authors. J Urol. 2022 06; 207(6):1245. Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. PMID: 35236091.
      View in: PubMed   Mentions:    Fields:    
    63. Prostate Cancer, Decisional Regret and Exercise. J Urol. 2022 05; 207(5):952-953. Eggener S, Siemens DR. PMID: 35080461.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245. Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. PMID: 35050703.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. Editorial Comment. J Urol. 2022 05; 207(5):1066. Eggener S. PMID: 35042391.
      View in: PubMed   Mentions:    Fields:    
    66. Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021. Eur Urol. 2022 02; 81(2):218. Grummet J, Eggener S. PMID: 34895925.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series. Urol Oncol. 2022 02; 40(2):18-24. Saoud R, Kristof TW, Judge C, Chumbalkar V, Antic T, Eggener S, Modi P. PMID: 34815169.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    68. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264. Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SE. PMID: 34775795.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    69. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377. Chatterjee A, Mercado C, Bourne RM, Yousuf A, Hess B, Antic T, Eggener S, Oto A, Karczmar GS. PMID: 34751615; PMCID: PMC8805656.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    70. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492. Tatjana A, Tjota MY, O'Donnell PH, Eggener SE, Agarwal PK, Haridas R, Segal J, Wang P. PMID: 34128116.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    71. Editorial Comment. J Urol. 2021 09; 206(3):668. Eggener SE. PMID: 34074115.
      View in: PubMed   Mentions:    Fields:    
    72. Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. Can J Urol. 2021 04; 28(2):10620-10624. Asghar AM, McIntosh AG, Smith ZL, Kocher NJ, Lee Z, Barashi NN, Li T, Raman JD, Eggener SE, Uzzo RG, Kutikov A. PMID: 33872561.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer? Eur Urol Oncol. 2022 04; 5(2):135-137. Vickers AJ, Russo G, Lilja H, Evans C, Schalken JA, Klein E, Eggener S. PMID: 33608234.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    74. Should Grade Group 1 (GG1) be called cancer? World J Urol. 2022 Jan; 40(1):15-19. Labbate CV, Paner GP, Eggener SE. PMID: 33432506.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    75. Reply by Authors. J Urol. 2021 03; 205(3):779. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. PMID: 33355501.
      View in: PubMed   Mentions: 1     Fields:    
    76. Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. Eur Urol. 2021 04; 79(4):552-553. Eggener SE, Agarwal PK. PMID: 33303242.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426. Shi Z, Platz EA, Wei J, Na R, Fantus RJ, Wang CH, Eggener SE, Hulick PJ, Duggan D, Zheng SL, Cooney KA, Isaacs WB, Helfand BT, Xu J. PMID: 33257031.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    78. An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC Case Rep. 2020 Dec; 2(15):2460-2464. Ali W, Nathan S, Funaki B, Eggener S, Bakris G. PMID: 34317194; PMCID: PMC8304536.
      View in: PubMed   Mentions:
    79. Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. Eur Urol Focus. 2021 Sep; 7(5):1137-1142. Saoud RM, Andolfi C, Aizen J, Wymer K, Burg M, Barashi N, Daneshmand S, Eggener S. PMID: 33121935.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    80. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):460-474. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. PMID: 32969590; PMCID: PMC8576374.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    81. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):475-483. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. PMID: 32976703; PMCID: PMC8555431.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    82. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. PMID: 33021440.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    83. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332. Sun C, Wang S, Chatterjee A, Medved M, Eggener S, Karczmar GS, Oto A. PMID: 32785769; PMCID: PMC7755698.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. Prev Med Rep. 2020 Dec; 20:101174. Press DJ, Pierce B, Lauderdale DS, Aschebrook-Kilfoy B, Lin Gomez S, Hedeker D, Wright NE, Fantus RJ, Bettencourt L, Ahsan H, Eggener S. PMID: 33088675; PMCID: PMC7566952.
      View in: PubMed   Mentions: 4  
    85. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854. Liauw SL, Ham SA, Das LC, Rudra S, Packiam VT, Koshy M, Weichselbaum RR, Becker YT, Bodzin AS, Eggener SE. PMID: 31728517; PMCID: PMC8453608.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    86. Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. Eur Urol. 2020 08; 78(2):161-162. Modi PK, Eggener SE. PMID: 32593531.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. PMID: 32516092; PMCID: PMC7430215.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    88. Editorial Comment. J Urol. 2020 08; 204(2):287. Eggener S. PMID: 32432506.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    89. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18. Labbate CV, Werntz RP, Galansky LB, Packiam VT, Eggener SE. PMID: 32305267.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    90. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343. Eggener SE, Rumble RB, Beltran H. PMID: 32048932.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    91. Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S31-S35. Werntz RP, Eggener SE. PMID: 32055483; PMCID: PMC6995846.
      View in: PubMed   Mentions: 2  
    92. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494. Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H. PMID: 31829902.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    93. Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer. 2020 02 01; 126(3):470-472. Eggener SE. PMID: 31742661.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712. Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey B. PMID: 31642740; PMCID: PMC8274953.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansPHPublic Health
    95. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. PMID: 31144591.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    96. Reply by Authors. J Urol. 2019 11; 202(5):958. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. PMID: 31364932.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Editorial Comment. J Urol. 2019 11; 202(5):942-943. Eggener S. PMID: 31364943.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. Eur Urol. 2019 11; 76(5):610-611. Porter J, Eggener S, Castle E, Pierorazio P. PMID: 31543365.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    99. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. PMID: 31502940; PMCID: PMC8274949.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    100. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178. Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. PMID: 31501508; PMCID: PMC7027969.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    101. Editorial Comment. J Urol. 2019 08; 202(2):263. Eggener S. PMID: 31067164.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    102. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281. Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. PMID: 31059667.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    103. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206. Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu S, Bagrodia A. PMID: 31272940.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    104. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800. Bhanvadia RR, Rodriguez J, Bagrodia A, Eggener SE. PMID: 31054211.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    105. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. PMID: 31128968.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    106. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692. Akthar AS, Liao C, Eggener SE, Liauw SL. PMID: 31113644.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    107. Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974. Pinsky PF, Black A, Daugherty SE, Hoover R, Parnes H, Smith ZL, Eggener S, Andriole GL, Berndt SI. PMID: 31067347; PMCID: PMC6690759.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    108. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75. Chatterjee A, He D, Fan X, Antic T, Jiang Y, Eggener S, Karczmar GS, Oto A. PMID: 31039019.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    109. International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138. Osterberg EC, Golan S, Pes MPL, Eggener SE, Petrut B, Singh SK, Sountoulides P, Türkeri LN, Wolf JS. PMID: 31009740.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. PMID: 30968729; PMCID: PMC6595543.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    111. Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252. Werntz RP, Eggener SE. PMID: 30962042.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66. Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. PMID: 30857555; PMCID: PMC6413449.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    113. Editorial Comment. J Urol. 2019 02; 201(2):266-267. Eggener S. PMID: 30634353.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    114. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153. van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ. PMID: 30671638; PMCID: PMC6763411.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    115. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. PMID: 31200839.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    116. A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology. 2019 04; 126:76-82. Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg S, Goldfischer E, Korman H, Bennett J, Newmark J, Denes BS. PMID: 30611659.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    117. Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care. Eur Urol. 2019 04; 75(4):635-636. Pierorazio P, Eggener S. PMID: 30578120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356. Sun C, Chatterjee A, Yousuf A, Antic T, Eggener S, Karczmar GS, Oto A. PMID: 30540213.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    119. Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy. Med Phys. 2019 Feb; 46(2):800-810. Knull E, Oto A, Eggener S, Tessier D, Guneyli S, Chatterjee A, Fenster A. PMID: 30447155.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    120. Region-specific microRNA signatures in the human epididymis. Asian J Androl. 2018 Nov-Dec; 20(6):539-544. Browne JA, Leir SH, Eggener SE, Harris A. PMID: 30058558; PMCID: PMC6219309.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    121. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380. Wang S, Fan X, Yousuf A, Eggener SE, Karczmar G, Oto A. PMID: 30291653.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    122. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615. He D, Chatterjee A, Fan X, Wang S, Eggener S, Yousuf A, Antic T, Oto A, Karczmar GS. PMID: 29702525; PMCID: PMC6512866.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    123. "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709. Weiner AB, Schaeffer EM, Eggener SE. PMID: 30224197.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    124. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Mol Hum Reprod. 2018 09 01; 24(9):433-443. Yang R, Browne JA, Eggener SE, Leir SH, Harris A. PMID: 30016502; PMCID: PMC6454485.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    125. Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190. Johnson SC, Smith ZL, Nottingham C, Schwen ZR, Thomas S, Fishman EK, Lee NJ, Pierorazio PM, Eggener SE. PMID: 30179635.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    126. Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468. Werntz RP, Pearce SM, Eggener SE. PMID: 29979235.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    127. Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18. Riedinger CB, Labbate C, Werntz RP, Eggener SE. PMID: 30170087.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    128. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604. Westin C, Chatterjee A, Ku E, Yousuf A, Wang S, Thomas S, Fan X, Eggener S, Karczmar G, Oto A. PMID: 29995499.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    129. Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. Eur Urol Oncol. 2018 12; 1(6):501-506. Barashi NS, Pearce SM, Cohen AJ, Pariser JJ, Packiam VT, Eggener SE. PMID: 31158094.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    130. Ablation energies for focal treatment of prostate cancer. World J Urol. 2019 Mar; 37(3):409-418. Lodeizen O, de Bruin M, Eggener S, Crouzet S, Ghai S, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T, de la Rosette J. PMID: 29943219; PMCID: PMC6424940.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    131. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93. Tretiakova M, Mehta V, Kocherginsky M, Minor A, Shen SS, Sirintrapun SJ, Yao JL, Alvarado-Cabrero I, Antic T, Eggener SE, Picken MM, Paner GP. PMID: 29770853.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    132. No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology. 2018 Jul; 117:31-35. Packiam VT, Nottingham CU, Cohen AJ, Eggener SE, Gerber GS. PMID: 29709434.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    133. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget. 2018 Apr 20; 9(30):21359-21365. Dinizo M, Shih W, Kwon YS, Eun D, Reese A, Giusto L, Trabulsi EJ, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu SD, Eggener S, Kim IY. PMID: 29765545; PMCID: PMC5940363.
      View in: PubMed   Mentions: 6     Fields:    
    134. Active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):195-196. Dall'Era MA, Davies BJ, Eggener S. PMID: 29732276; PMCID: PMC5911535.
      View in: PubMed   Mentions:
    135. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10; 378(19):1767-1777. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, PRECISION Study Group Collaborators. PMID: 29552975; PMCID: PMC9084630.
      View in: PubMed   Mentions: 1133     Fields:    Translation:Humans
    136. Novel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183. Werntz RP, Eggener SE. PMID: 29232270.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    137. Region-specific innate antiviral responses of the human epididymis. Mol Cell Endocrinol. 2018 09 15; 473:72-78. Browne JA, Leir SH, Eggener SE, Harris A. PMID: 29339104; PMCID: PMC6045438.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    138. Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. Rev Urol. 2018; 20(2):63-68. Pieczonka CM, Twardowski P, Renzulli J, Hafron J, Boldt-Houle DM, Atkinson S, Eggener S. PMID: 30288142; PMCID: PMC6168320.
      View in: PubMed   Mentions: 5  
    139. Focal Therapy for Localized Prostate Cancer. Rev Urol. 2018; 20(4):143-144. Eggener S. PMID: 30787672; PMCID: PMC6375004.
      View in: PubMed   Mentions: 1  
    140. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517. Bernstein AN, Shoag JE, Golan R, Halpern JA, Schaeffer EM, Hsu WC, Nguyen PL, Sedrakyan A, Chen RC, Eggener SE, Hu JC. PMID: 29288121; PMCID: PMC6530582.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    141. Testicular Cancer: Epidemiology, Diagnosis, and Management. Med Clin North Am. 2018 Mar; 102(2):251-264. Smith ZL, Werntz RP, Eggener SE. PMID: 29406056.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    142. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. PMID: 29236593; PMCID: PMC6075860.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    143. Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. Eur Urol. 2018 06; 73(6):897-898. Eggener S. PMID: 29224914.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    144. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 12; 20(4):442. Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. PMID: 29125150.
      View in: PubMed   Mentions: 5     Fields:    
    145. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018 Mar; 56(2):187-196. Rodriguez JF, Eggener SE. PMID: 29420975.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    146. Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. Eur Urol Focus. 2017 12; 3(6):522-523. Eggener S. PMID: 29174615.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy. Evid Based Med. 2017 12; 22(6):222. Packiam VT, Eggener SE. PMID: 29127213.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    148. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609. Rodriguez JF, Liauw SL, Eggener SE. PMID: 29107276.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    149. Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. JSLS. 2017 Oct-Dec; 21(4). Wenger H, Razmaria A, Eggener S, Raman JD. PMID: 29279663; PMCID: PMC5740780.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    150. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. Evid Based Med. 2017 10; 22(5):192. Smith ZL, Eggener SE. PMID: 28814450.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    151. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81. Smith ZL, Eggener SE, Murphy AB. PMID: 28808871.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    152. Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model. Urology. 2017 Nov; 109:32-37. Chow AK, Sherer BA, Yura E, Kielb S, Kocjancic E, Eggener S, Turk T, Park S, Psutka S, Abern M, Latchamsetty KC, Coogan CL. PMID: 28801218.
      View in: PubMed   Mentions: 5     Fields:    
    153. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288. Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. PMID: 28631720.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    154. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032. Tallman JE, Pearce SM, Kuchta K, Helfand BT, Eggener SE. PMID: 28551443.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    155. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838. Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, Pinto PA, Bjurlin MA, Eggener S. PMID: 28483574; PMCID: PMC7905434.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansPHPublic Health
    156. Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017 04 01; 28(4):899-902. Wymer KM, Daneshmand S, Pierorazio PM, Pearce SM, Harris KT, Eggener SE. PMID: 28137740.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    157. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017 Apr; 24(2):8714-8720. Ericson KJ, Wenger HC, Rosen AM, Kiriluk KJ, Gerber GS, Paner GP, Eggener SE. PMID: 28436357.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    158. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249. Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker C. PMID: 28318726.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    159. Influence of pathologist experience on positive surgical margins following radical prostatectomy. Urol Oncol. 2017 07; 35(7):461.e1-461.e6. Tallman JE, Packiam VT, Wroblewski KE, Paner GP, Eggener SE. PMID: 28302349; PMCID: PMC5476525.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    160. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497. Kane CJ, Eggener SE, Shindel AW, Andriole GL. PMID: 28753804.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    161. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349. Verma S, Rosenkrantz AB, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. PMID: 27670878.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    162. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20; 35(6):668-680. Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. PMID: 28095147.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    163. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol. 2017 09; 72(3):455-460. Anderson BB, Oberlin DT, Razmaria AA, Choy B, Zagaja GP, Shalhav AL, Meeks JJ, Yang XJ, Paner GP, Eggener SE. PMID: 27986368.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    164. Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. Eur Urol. 2017 04; 71(4):515-516. Eggener S. PMID: 27743755.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    165. Perspectives on International Urological Volunteerism: A Survey of IVUmed Resident Scholar Alumni. Urol Pract. 2017 Mar; 4(2):176-182. Murthy P, Malik RD, McCammon KA, Schneck FX, deVries C, Chrouser K, Eggener SE. PMID: 37592674.
      View in: PubMed   Mentions: 1     Fields:    
    166. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6. Choy B, Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE, Paner GP. PMID: 27379821.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    167. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6. Wenger H, Weiner AB, Razmaria A, Paner GP, Eggener SE. PMID: 27692833.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    168. Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. J Urol. 2017 03; 197(3 Pt 1):684-689. Wymer KM, Pearce SM, Harris KT, Pierorazio PM, Daneshmand S, Eggener SE. PMID: 27663460.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    169. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252. Weiner AB, Pearce SM, Eggener SE. PMID: 27626903.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    170. Editorial Comment. J Urol. 2016 12; 196(6):1668-1669. Eggener SE. PMID: 27613117.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    171. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017 01; 71(1):17-34. Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M. PMID: 27595377.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    172. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016 12; 196(6):1670-1675. Eggener SE, Yousuf A, Watson S, Wang S, Oto A. PMID: 27449263.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    173. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. PMID: 27431496.
      View in: PubMed   Mentions: 123     Fields:    Translation:Humans
    174. The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. J Endourol. 2016 09; 30(9):997-1003. Packiam VT, Nottingham CU, Cohen AJ, Pearce SM, Shalhav AL, Eggener SE. PMID: 27338841.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    175. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. PMID: 27320841; PMCID: PMC6364689.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    176. Erratum to "HNF1 regulates critical processes in the human epididymis epithelium" [Mol. Cell. Endocrinol. 425 (2016) 94-102]. Mol Cell Endocrinol. 2016 Jun 15; 428:174. Browne JA, Yang R, Eggener SE, Leir SH, Harris A. PMID: 27147477.
      View in: PubMed   Mentions:    Fields:    
    177. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482. Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE. PMID: 27234998.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    178. Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3. Drazer MW, Eggener SE. PMID: 27182910.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    179. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Oct; 34(10):1373-82. Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. PMID: 26892160; PMCID: PMC5026990.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    180. Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81. Pearce SM, Pariser JJ, Karrison T, Patel SG, Eggener SE. PMID: 26860793.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    181. HNF1 regulates critical processes in the human epididymis epithelium. Mol Cell Endocrinol. 2016 Apr 15; 425:94-102. Browne JA, Yang R, Eggener SE, Leir SH, Harris A. PMID: 26808453; PMCID: PMC4799753.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    182. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185. Son CH, Melotek JM, Liao C, Hubert G, Pelizzari CA, Eggener SE, Liauw SL. PMID: 26961716.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    183. National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. J Urol. 2016 May; 195(5):1383-1389. Weiner AB, Conti RM, Eggener SE. PMID: 26707507.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    184. The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol. 2016 Feb; 13(2):91-8. Valerio M, Emberton M, Eggener SE, Ahmed HU. PMID: 26666364.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    185. Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Mol Hum Reprod. 2016 Feb; 22(2):69-82. Browne JA, Yang R, Leir SH, Eggener SE, Harris A. PMID: 26612782; PMCID: PMC4733224.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    186. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883. Ward JF, Eggener SE. PMID: 26112488; PMCID: PMC4814962.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    187. Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int. 2016 06; 117(6):914-22. Golan S, Eggener S, Subotic S, Barret E, Cormio L, Naito S, Tefekli A, Pilar Laguna Pes M. PMID: 26389787.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    188. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016 May; 34(5):687-93. Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, Dangle P, Shalhav AL, Crist H, Raman JD, Joel DeCastro G, Harik L, Paroder M, Uzzo RG, Kutikov A, Eggener SE. PMID: 26407582.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    189. Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55. Eggener S. PMID: 26382084.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    190. Prostate Cancer Screening. JAMA. 2015 Aug 25; 314(8):825-6. Eggener SE, Cifu AS, Nabhan C. PMID: 26305653.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    191. Known Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer. Eur Urol Focus. 2015 Sep; 1(2):171-172. Eggener S. PMID: 28723430.
      View in: PubMed   Mentions:    Fields:    
    192. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82. Packiam VT, Patel SG, Pariser JJ, Richards KA, Weiner AB, Paner GP, VanderWeele DJ, Zagaja GP, Eggener SE. PMID: 26196240.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    193. Giant Multilocular Cystadenoma of the Prostate. Radiographics. 2015 Jul-Aug; 35(4):1051-5. Baad M, Ericson K, Yassan L, Oto A, Eggener S, Nottingham CU, Richards KA, Thomas S. PMID: 26172350.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    194. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23. Drazer MW, Huo D, Eggener SE. PMID: 26056181.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansPHPublic Health
    195. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98. Pearce SM, Liauw SL, Eggener SE. PMID: 26216816.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    196. The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World J Urol. 2016 Feb; 34(2):269-74. Pearce SM, Pariser JJ, Patel SG, Anderson BB, Eggener SE, Zagaja GP. PMID: 26045402.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    197. Corneal abrasion in hysterectomy and prostatectomy: role of laparoscopic and robotic assistance. Anesthesiology. 2015 May; 122(5):994-1001. Sampat A, Parakati I, Kunnavakkam R, Glick DB, Lee NK, Tenney M, Eggener S, Roth S. PMID: 25734923; PMCID: PMC5836305.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    198. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44. Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. PMID: 25913390.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    199. EVALUATING THE EMERGING TRENDS IN THE DIAGNOSIS AND TREATMENT OF KIDNEY CANCER—THE RENAL MASS GLOBAL STUDY. J Endourol. 2015 May; 29(5):495-7. Golan S, Eggener S. PMID: 25884106.
      View in: PubMed   Mentions: 1     Fields:    
    200. Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34. Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT. PMID: 25849602; PMCID: PMC4551510.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    201. Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes. Urol Oncol. 2015 Apr; 33(4):163.e1-6. Pearce SM, Richards KA, Patel SG, Pariser JJ, Eggener SE. PMID: 25708953.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    202. Updated Survey of Social Media Use by Members of the American Urological Association. Urol Pract. 2015 May; 2(3):138-143. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Griebling TL, Eggener SE, American Urological Association Social Media Work Group. PMID: 37559256.
      View in: PubMed   Mentions: 4     Fields:    
    203. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94. Ledezma RA, Negron E, Razmaria AA, Dangle P, Eggener SE, Shalhav AL, Zagaja GP. PMID: 25701128.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    204. How active should active surveillance be? BJU Int. 2015 Feb; 115(2):176-7. Eggener S. PMID: 25604714.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    205. Population based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy. J Urol. 2015 Mar; 193(3):826-31. Weiner AB, Murthy P, Richards KA, Patel SG, Eggener SE. PMID: 25632850.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    206. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7. Weiner AB, Patel SG, Eggener SE. PMID: 25624093.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    207. Characterization of primary cultures of adult human epididymis epithelial cells. Fertil Steril. 2015 Mar; 103(3):647-54.e1. Leir SH, Browne JA, Eggener SE, Harris A. PMID: 25542823; PMCID: PMC4346407.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    208. Indications for adrenalectomy during radical nephrectomy for renal cancer. Arab J Urol. 2014 Dec; 12(4):304-8. Gabr AH, Steinberg Z, Eggener SE, Stuart Wolf J. PMID: 26019967; PMCID: PMC4434884.
      View in: PubMed   Mentions: 1  
    209. Preoperative nuclear renal scan underestimates renal function after radical nephrectomy. Urology. 2014 Dec; 84(6):1402-6. Bachrach L, Negron E, Liu JS, Su YK, Paparello JJ, Eggener S, Kundu SD. PMID: 25312551.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    210. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015 Apr; 67(4):771-7. Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HU. PMID: 25281389; PMCID: PMC4410301.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    211. The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J Endourol. 2014 Nov; 28(11):1338-44. Richards KA, Negron E, Cohn JA, Steinberg Z, Eggener SE, Shalhav AL. PMID: 24935823; PMCID: PMC4382827.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    212. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102. Weiner AB, Patel SG, Etzioni R, Eggener SE. PMID: 25106900.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    213. Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005. Urol Oncol. 2014 Aug; 32(6):935-6. Eggener S. PMID: 25087672.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    214. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Urol Oncol. 2014 Aug; 32(6):936-7. Eggener S. PMID: 25087673.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    215. Commentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD. J Clin Oncol 2013; 31(24):2991-7. [Epub 2013 Jun 17]. doi: 10.1200/JCO.2012.47.0302. Urol Oncol. 2014 Aug; 32(6):936. Eggener S. PMID: 25087674.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    216. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May; 33(5):623-31. Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. PMID: 25030752.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    217. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7. Cohen A, Richards KA, Patel S, Weiner A, Eggener SE, Szmulewitz RZ. PMID: 25044254.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    218. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91. Weiner AB, Patel SG, Richards KA, Szmulewitz RZ, Eggener SE. PMID: 25027862.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    219. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34. Hu JC, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, Trinh QD, Sun M, Nguyen PL, Lipsitz SR. PMID: 25017694.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    220. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014 Aug 10; 32(23):2471-8. Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JC. PMID: 25002728; PMCID: PMC4121505.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    221. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67. Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HU. PMID: 24965212.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    222. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE, American Urological Association Social Media Work Group. PMID: 24274744.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    223. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar; 33(3):351-7. Eggener SE, Clark MA, Shikanov S, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Harel M, Cambio J, Shalhav AL, Raman JD. PMID: 24817142.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    224. Laser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014 May; 24(3):236-40. Wenger H, Yousuf A, Oto A, Eggener S. PMID: 24625427; PMCID: PMC4071166.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    225. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77. Hansford BG, Karademir I, Peng Y, Jiang Y, Karczmar G, Thomas S, Yousuf A, Antic T, Eggener S, Oto A. PMID: 24703469.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    226. Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978. Urol Oncol. 2014 May; 32(4):513-4. Eggener S. PMID: 24767688.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    227. Elastographic search for the (high-grade) tree in the (prostatic) forest. BJU Int. 2014 Apr; 113(4):514-5. Eggener S. PMID: 24629082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    228. Editorial comment. J Urol. 2014 Jul; 192(1):81. Eggener S. PMID: 24703979.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    229. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 2014 Apr 14; 25(4):455-68. Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KP. PMID: 24656772; PMCID: PMC4443692.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansAnimalsCells
    230. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2. Weiner AB, Etzioni R, Eggener SE. PMID: 24630416; PMCID: PMC4155020.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    231. Apparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol. 2014 Mar; 202(3):W247-53. Peng Y, Jiang Y, Antic T, Sethi I, Schmid-Tannwald C, Eggener S, Oto A. PMID: 24555621.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    232. Renal hemorrhagic actinomycotic abscess in pregnancy. Infect Dis Rep. 2014 Feb 18; 6(1):5157. Smid MC, Bhardwaj NR, Di Giovanni LM, Eggener S, Torre MD. PMID: 24757509; PMCID: PMC3987246.
      View in: PubMed   Mentions: 3  
    233. Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014 May; 271(2):461-71. Peng Y, Jiang Y, Antic T, Giger ML, Eggener SE, Oto A. PMID: 24533870.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    234. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8. Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE. PMID: 24523016.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansPHPublic Health
    235. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT. PMID: 24444476.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    236. The volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function. J Endourol. 2014 Feb; 28(2):196-200. Golan S, Patel AR, Eggener SE, Shalhav AL. PMID: 24033335.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    237. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8. Karademir I, Shen D, Peng Y, Liao S, Jiang Y, Yousuf A, Karczmar G, Sammet S, Wang S, Medved M, Antic T, Eggener S, Oto A. PMID: 24147475; PMCID: PMC4354695.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    238. Revisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum? J Magn Reson Imaging. 2014 Jan; 39(1):167-71. Hansford BG, Peng Y, Jiang Y, Al-Ahmadie H, Eggener S, Yousuf A, Oto A. PMID: 24123318.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    239. Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7. Pearce S, Steinberg Z, Eggener S. PMID: 23907555.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    240. Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation. BJU Int. 2014 Apr; 113(4):592-7. Patel A, Golan S, Razmaria A, Prasad S, Eggener S, Shalhav A. PMID: 24006926.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    241. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15; 119(22):3992-4002. Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF. PMID: 24006289; PMCID: PMC4880351.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    242. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014 Apr; 65(4):675-80. Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP, Rabah DM, Eastham JA, Scardino PT. PMID: 24035631.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    243. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int. 2013 Nov; 112(7):925-9. Eggener SE, Large MC, Gerber GS, Pettus J, Yossepowitch O, Smith ND, Kundu S, Kunnavakkam R, Zorn K, Raman JD. PMID: 23890317.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    244. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014 May; 65(5):918-27. Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, Tewari A, Touijer K, Wilson T, Zorn KC, Eggener SE. PMID: 23721959.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    245. Words of wisdom: Re: Do adenocarcinomas of the prostate with Gleason Score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Eur Urol. 2013 May; 63(5):960. Richards K, Eggener S. PMID: 23541252.
      View in: PubMed   Mentions:    Fields:    
    246. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, START Consortium. PMID: 23537686.
      View in: PubMed   Mentions: 168     Fields:    Translation:Humans
    247. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40. Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S. PMID: 23440319.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    248. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013 Jun; 267(3):797-806. Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, Eggener S, Antic T, Oto A. PMID: 23440325; PMCID: PMC6940014.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    249. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. Radiology. 2013 Jun; 267(3):787-96. Peng Y, Jiang Y, Yang C, Brown JB, Antic T, Sethi I, Schmid-Tannwald C, Giger ML, Eggener SE, Oto A. PMID: 23392430; PMCID: PMC6940008.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    250. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53. Lane BR, Golan S, Eggener S, Tobert CM, Kahnoski RJ, Kutikov A, Smaldone M, Whelan CM, Shalhav A, Uzzo RG. PMID: 23313207.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    251. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B. PMID: 23234624.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    252. The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol. 2013 Aug; 31(4):977-82. Cosentino M, Breda A, Sanguedolce F, Landman J, Stolzenburg JU, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D'Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D'Ancona FC, Polascik TJ, Muschter R, Leppert TJ, Villavicencio H. PMID: 23242033.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    253. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63. Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H, Zagaja G, Eggener S, Brendler C, Shalhav A. PMID: 22759270.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    254. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84. Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A. PMID: 22717242.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    255. Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):138-44. Corbin KS, Kunnavakkam R, Eggener SE, Liauw SL. PMID: 24674317.
      View in: PubMed   Mentions: 7     Fields:    
    256. Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol. 2012 Jun; 19(3):6292. Eggener S. PMID: 22704316.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    257. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics. 2012 May-Jun; 32(3):819-37. Yacoub JH, Verma S, Moulton JS, Eggener S, Aytekin O. PMID: 22582361.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    258. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. PMID: 22535850.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    259. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012 Jun; 187(6):1978-83. Patel AR, Prasad SM, Shih YC, Eggener SE. PMID: 22498216.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    260. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012 Oct; 110(7):942-8. Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M. PMID: 22462566.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    261. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73. Soylu FN, Eggener S, Oto A. PMID: 22399364.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    262. Environmental toxicology of testicular cancer. Urol Oncol. 2012 Mar-Apr; 30(2):212-5. Meeks JJ, Sheinfeld J, Eggener SE. PMID: 22385991.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsPHPublic Health
    263. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol. 2012 Apr; 26(4):398-402. Clements T, Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. PMID: 22192113.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    264. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM. PMID: 22109293.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    265. Hazard of prostate cancer specific mortality after radical prostatectomy. J Urol. 2012 Jan; 187(1):124-7. Shikanov S, Eggener SE. PMID: 22114813.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    266. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):106-10. Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. PMID: 22083265.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    267. Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters. Urol Oncol. 2011 Nov-Dec; 29(6):826-8. Patel AR, Eggener SE. PMID: 22078406.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    268. Focal therapy for clinically localized prostate cancer. Arch Esp Urol. 2011 Oct; 64(8):815-22. Marchetti P, Eggener S. PMID: 22052762.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    269. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61. Fan X, Haney CR, Agrawal G, Pelizzari CA, Antic T, Eggener SE, Sethi I, River JN, Zamora M, Karczmar GS, Oto A. PMID: 21928309.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    270. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013 Aug; 31(6):904-8. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. PMID: 21906967.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    271. Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol. 2011 Sep; 25(9):1435-41. Lifshitz DA, Shikanov SA, Razmaria AA, Eggener SE, Liao C, Chang A, Shalhav AL. PMID: 21797760.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    272. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9. Rosen A, Jayram G, Drazer M, Eggener SE. PMID: 21612857.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    273. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. PMID: 21444863; PMCID: PMC4821471.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansPHPublic Health
    274. Editorial comment. J Urol. 2011 Apr; 185(4):1254-5. Eggener S. PMID: 21334019.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    275. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5. Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. PMID: 21320275.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    276. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar; 185(3):869-75. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ. PMID: 21239008; PMCID: PMC4058776.
      View in: PubMed   Mentions: 242     Fields:    Translation:Humans
    277. Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J Endourol. 2011 Apr; 25(4):699-703. Katz MH, Shikanov S, Sun M, Abdollah F, Budaeus L, Gong EM, Eggener SE, Steinberg GD, Zagaja GP, Shalhav AL, Karakiewicz PI, Zorn KC. PMID: 21226623.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    278. Chronic kidney disease before and after partial nephrectomy. J Urol. 2011 Jan; 185(1):43-8. Clark MA, Shikanov S, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Shalhav AL, Eggener SE. PMID: 21074205.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    279. Chronic Kidney Disease Epidemiology Collaboration versus Modification of Diet in Renal Disease equations for renal function evaluation in patients undergoing partial nephrectomy. J Urol. 2010 Nov; 184(5):1867-71. Shikanov S, Clark MA, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Huang WC, Shalhav AL, Eggener SE. PMID: 20846677.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    280. Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy. J Urol. 2010 Nov; 184(5):1872-6. Gautam G, Lifshitz D, Shikanov S, Moore JM, Eggener SE, Shalhav AL, Chang A. PMID: 20850146.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    281. TNM staging for renal cell carcinoma: time for a new method. Eur Urol. 2010 Oct; 58(4):517-9; discussion 519-21. Eggener S. PMID: 20728266.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    282. Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]. Eur Urol. 2010 Oct; 58(4):644. Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. PMID: 28065298.
      View in: PubMed   Mentions: 1     Fields:    
    283. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73. Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. PMID: 20478585.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    284. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul; 58(1):57-64. Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. PMID: 20378241.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    285. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5. Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D, Bosl GJ, Sheinfeld J. PMID: 20299079; PMCID: PMC3654386.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    286. Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study. J Urol. 2010 May; 183(5):1714-8. Shikanov S, Lifshitz D, Chan AA, Okhunov Z, Ordonez MA, Wheat JC, Matin SF, Landman J, Wolf JS, Eggener SE, Shalhav AL. PMID: 20299052.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    287. Orthotopic neobladder versus Indiana pouch in women: a comparison of health related quality of life outcomes. J Urol. 2010 Jan; 183(1):201-6. Large MC, Katz MH, Shikanov S, Eggener SE, Steinberg GD. PMID: 19913836.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    288. Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol. 2010 Jan-Mar; 26(1):92-7. Jayram G, Szmulewitz RZ, Eggener SE. PMID: 20535293; PMCID: PMC2878446.
      View in: PubMed   Mentions: 2  
    289. Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'. Br J Cancer. 2009 Dec 15; 101(12):2057-8; author reply 2059. Eggener S, Gonzalgo M, Yossepowitch O. PMID: 19997112; PMCID: PMC2795433.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    290. Laparoscopic partial nephrectomy: a single-center evolving experience. Urology. 2010 Feb; 75(2):282-7. Lifshitz DA, Shikanov SA, Deklaj T, Katz MH, Zorn KC, Eggener SE, Shalhav AL. PMID: 19962732.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    291. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75. Large MC, Sheinfeld J, Eggener SE. PMID: 19840015.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    292. Active surveillance for low-risk localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):974-9. Large MC, Eggener SE. PMID: 19947349.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    293. Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons. J Urol. 2009 Sep; 182(3):1126-32. Zorn KC, Gautam G, Shalhav AL, Clayman RV, Ahlering TE, Albala DM, Lee DI, Sundaram CP, Matin SF, Castle EP, Winfield HN, Gettman MT, Lee BR, Thomas R, Patel VR, Leveillee RJ, Wong C, Badlani GH, Rha KH, Eggener SE, Wiklund P, Mottrie A, Atug F, Kural AR, Joseph JV, Members of the Society of Urologic Robotic Surgeons. PMID: 19625032.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    294. Laparoscopic partial nephrectomy: predictors of prolonged warm ischemia. J Urol. 2009 Sep; 182(3):860-5. Lifshitz DA, Shikanov S, Jeldres C, Deklaj T, Karakiewicz PI, Zorn KC, Eggener SE, Shalhav AL. PMID: 19616257.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    295. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol. 2009 Aug; 175(2):882-90. Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, Michalak M, Dhir R, Wang Z. PMID: 19608864; PMCID: PMC2716982.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    296. Knotless closure of the collecting system and renal parenchyma with a novel barbed suture during laparoscopic porcine partial nephrectomy. J Endourol. 2009 Jul; 23(7):1157-60. Shikanov S, Wille M, Large M, Lifshitz DA, Zorn KC, Shalhav AL, Eggener SE. PMID: 19530906.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    297. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7. Eggener SE, Raman JD. PMID: 19467675.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    298. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009 Jul; 182(1):139-44. Shikanov S, Song J, Royce C, Al-Ahmadie H, Zorn K, Steinberg G, Zagaja G, Shalhav A, Eggener S. PMID: 19450829.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    299. Editorial comment on: Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol. 2009 Aug; 56(2):361-2. Eggener SE. PMID: 19467770.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    300. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol. 2009 May; 19(3):268-73. Jayram G, Eggener SE. PMID: 19342957.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    301. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83. Katz MH, Eggener SE. PMID: 19363613.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    302. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):472. Eggener S. PMID: 19359087.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    303. The clinical diversity of postchemotherapy germ cell teratoma. Cancer. 2009 Mar 15; 115(6):1138-41. Eggener SE. PMID: 19165804.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    304. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009 Apr; 181(4):1635-41; discussion 1641. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B. PMID: 19233410; PMCID: PMC4237227.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    305. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4. Orvieto M, Eggener S. PMID: 19200640.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    306. Robotic-assisted partial cystectomy for recurrent extra-adrenal pheochromocytoma. J Robot Surg. 2009 Mar; 3(1):41-3. Jayram G, Msezane LE, Angelos P, Eggener SE. PMID: 27628452.
      View in: PubMed   Mentions:    Fields:    
    307. Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. Adv Urol. 2009; 181927. Kundu SD, Eggener SE. PMID: 19190765; PMCID: PMC2630418.
      View in: PubMed   Mentions: 2  
    308. Editorial comment on: Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. Eur Urol. 2009 Apr; 55(4):900-1. Reynolds WS, Eggener SE. PMID: 19171420.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    309. Comparison of models to predict clinical failure after radical prostatectomy. Cancer. 2009 Jan 15; 115(2):303-10. Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ, Scardino PT. PMID: 19025977; PMCID: PMC2740715.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    310. Editorial comment on: Reducing laparoscopic radical prostatectomy false-positive margin rates using cyanoacrylate tissue glue. Eur Urol. 2009 Oct; 56(4):658. Eggener SE. PMID: 19091455.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    311. Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009 Feb; 73(2):316-22. Wiltz AL, Shikanov S, Eggener SE, Katz MH, Thong AE, Steinberg GD, Shalhav AL, Zagaja GP, Zorn KC. PMID: 18952266.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    312. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld J. PMID: 18936477; PMCID: PMC2651099.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    313. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol. 2008 Dec; 180(6):2436-40. Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, Shalhav AL, Zorn KC. PMID: 18930486.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    314. Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. ScientificWorldJournal. 2008 Oct 03; 8:963-73. Eggener SE, Coleman JA. PMID: 18836668; PMCID: PMC2692990.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    315. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. PMID: 18801515; PMCID: PMC2919316.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    316. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. PMID: 18635225; PMCID: PMC2570431.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    317. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009 Mar; 55(3):616. Eggener S. PMID: 18639973.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    318. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008 Jul 01; 113(1):84-96. Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, Karellas ME, Karanikolas NT, Kagiwada MA. PMID: 18470927; PMCID: PMC3985136.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    319. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM. PMID: 18538735; PMCID: PMC2732022.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCells
    320. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. PMID: 18423758; PMCID: PMC2704565.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    321. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008 Jun; 71(6):1016-9. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ. PMID: 18358515.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    322. Laparoscopic radical prostatectomy: ten years later, time for evidence-based foundation. Eur Urol. 2008 Jul; 54(1):4-7. Eggener SE, Guillonneau B. PMID: 18339477.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    323. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L, International Task Force on Prostate Cancer and the Focal Lesion Paradigm. PMID: 17936815.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    324. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9. Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ, Scardino PT, Eastham JA. PMID: 17950521; PMCID: PMC2637146.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    325. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J. PMID: 17906201.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    326. Editorial comment on: Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007 Oct; 52(4):1050-1. Eggener S. PMID: 17933029.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    327. Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug; 9(8):643-51. Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, Jiang F, Pochapsky TC, Hedstrom L, Wang Z. PMID: 17786183; PMCID: PMC1950434.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    328. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15; 13(14):4130-8. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT. PMID: 17634540; PMCID: PMC2660867.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    329. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug; 178(2):493-9; discussion 499. Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA. PMID: 17561152.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    330. Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology. 2007 Jun; 69(6):1128-33. Eggener SE, Yossepowitch O, Serio AM, Vickers AJ, Scardino PT, Eastham JA. PMID: 17572200.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    331. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. PMID: 17296380.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    332. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35. Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J. PMID: 17177200.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    333. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006 Nov; 68(5):988-92. Pettus JA, Eggener SE, Shabsigh A, Yanke B, Snyder ME, Serio A, Vickers A, Russo P, Donat SM. PMID: 17113889.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    334. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ. PMID: 17138126.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    335. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007 Apr; 51(4):940-7; discussion 947-8. Yossepowitch O, Bianco FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. PMID: 17125912; PMCID: PMC2646889.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    336. Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function. J Urol. 2006 Oct; 176(4 Pt 1):1339-43; discussion 1343. Yossepowitch O, Eggener SE, Serio A, Huang WC, Snyder ME, Vickers AJ, Russo P. PMID: 16952626.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    337. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006 Oct; 176(4 Pt 1):1399-403. Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ. PMID: 16952643.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    338. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol. 2006 Aug; 176(2):482-5. Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G. PMID: 16813873.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    339. NMP22 and surveillance for recurrent bladder cancer. JAMA. 2006 Jul 05; 296(1):45; author reply 45-6. Eggener S, Herr H. PMID: 16820545.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    340. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. PMID: 16809736.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans
    341. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate. 2006 Apr 01; 66(5):495-502. Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, Roehl KA, Wang Z. PMID: 16372330.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    342. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005 Dec; 174(6):2154-7, discussion 2157. Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. PMID: 16280754.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    343. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol. 2005 Aug; 174(2):500-4. Eggener SE, Roehl KA, Catalona WJ. PMID: 16006880.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    344. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4905-11. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. PMID: 16000589.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    345. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. PMID: 15992903.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    346. Magnetic resonance angiography for the nonpalpable testis: a cost and cancer risk analysis. J Urol. 2005 May; 173(5):1745-9; discussion 1749-50. Eggener SE, Lotan Y, Cheng EY. PMID: 15821574.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    347. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5. Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ. PMID: 15758725.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    348. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004 Dec; 172(6 Pt 1):2227-31. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. PMID: 15538237.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    349. Plasma cell infiltration of the urinary bladder. Urology. 2004 Jul; 64(1):156-7. Thaxton CS, Eggener SE, Schaeffer AJ. PMID: 15245959.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    350. Bilateral pulmonary artery tumour emboli from renal carcinoma. Lancet Oncol. 2004 Mar; 5(3):173. Eggener SE, Dalton DP. PMID: 15003200.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    351. Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5. Eggener SE, Abrahams A, Keeler TC. PMID: 15028471.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    352. Renal tumors in young adults. J Urol. 2004 Jan; 171(1):106-10. Eggener SE, Rubenstein JN, Smith ND, Nadler RB, Kontak J, Flanigan RC, Waters WB, Picken M, Campbell SC, Rubenstein JR. PMID: 14665855.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    353. Urolithiasis associated with topiramate. Int Braz J Urol. 2004 Jan-Feb; 30(1):29-30; discussion 30-1. Eggener S, Kim SC, User HM, Pazona J, Nadler RB. PMID: 15707510.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    354. Penile refracture: case report. J Trauma. 2003 Oct; 55(4):793-4. Eggener SE, Stern JA, Smith ND, Gonzalez CM. PMID: 14566143.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    355. A noninfectious source of renal gas: embolization. J Urol. 2003 Sep; 170(3):913. Eggener SE, Hua V, Schaeffer AJ, Smith ND. PMID: 12913729.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    356. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003 Apr; 169(4):1219-28. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. PMID: 12629332.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimals
    357. The etiology of urolithiasis in HIV infected patients. J Urol. 2003 Feb; 169(2):475-7. Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith ND. PMID: 12544290.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    358. Occlusion of an intraluminal endovascular stent graft after treatment of a ureteral-iliac artery fistula. Urology. 2002 Nov; 60(5):912. Rodriguez HE, Eggener SE, Podbielski FJ, Brown AM, Amble S, Clark ET, Smith ND. PMID: 12429336.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    359. Long-term survival after "drop metastases" of renal cell carcinoma to the bladder. Urology. 2002 Oct; 60(4):697. Raviv S, Eggener SE, Williams DH, Garnett JE, Pins MR, Smith ND. PMID: 12385938.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    360. Irritative voiding symptoms and microscopic hematuria caused by intraperitoneal calcified fat necrosis. Urology. 2002 Mar; 59(3):444. Rubenstein JN, Hairston JC, Eggener SE, Gonzalez CM. PMID: 11880093.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    361. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002 Mar; 167(3):1469-74. Reiher F, Ozer O, Pins M, Jovanovic BD, Eggener S, Campbell SC. PMID: 11832772.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    362. Anatomy of the rectourethralis muscle. Eur Urol. 2002 Jan; 41(1):94-100. Brooks JD, Eggener SE, Chao WM. PMID: 11999473.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    363. Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension. Rev Urol. 2002; 4(4):192-5. Rubenstein JN, Eggener SE, Pins MR, Rosner K, Chugh S, Campbell SC. PMID: 16985680; PMCID: PMC1475994.
      View in: PubMed   Mentions: 6  
    364. Bladder lipoma. J Urol. 2001 Oct; 166(4):1395. Eggener SE, Hairston J, Rubenstein JN, Gonzalez CM. PMID: 11547089.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    365. The power of the pen: medical journalism and public awareness. JAMA. 1998 May 06; 279(17):1400. Eggener S. PMID: 9582053.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    366. Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol. 1994 Oct 15; 480 ( Pt 2):361-8. Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJ. PMID: 7869251; PMCID: PMC1155852.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCTClinical Trials
    Scott's Networks
    Concepts (618)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (52)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California